Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling study of risperidone in Chinese schizophrenia patients

Trial Profile

Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling study of risperidone in Chinese schizophrenia patients

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 28 Mar 2016 New trial record
    • 23 Mar 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top